Highlight Topics of EASD 2016 at Germany


Please find the highlight topics presented at EASD, European Association for the Study of Diabetes. September 12-16, 2016, Munich, Germany.

· Insulin glargine 300 Units/mL experienced a consistently lower rate of confirmed or severe hypoglycemia both at night and at any time of the day compared with those treated with insulin glargine 100 Units/mL, at all levels of HbA1c.

· iGlarLixi, titratable fixed-ratio combination of insulin glargine and lixisenatide, offers greater control of PPG in T2DM compared to insulin glargine alone.

· Semaglutide, an investigational GLP-1RA once-weekly, significantly improved glycemic control compared to placebo.

· Patients treated with Semaglutide, had a significant 26% lower risk of the primary composite outcome of first occurrence of CV death, nonfatal myocardial infarction (MI), or nonfatal stroke over 2 years compared with those receiving placebo in the SUSTAIN-6 trial.

· Onset of type 1 diabetes is just as likely to occur in people older than 30 years of age as in those younger, new research shows.

· First Data on GLP-1 Agonist/SGLT2 Inhibitor Combo in Diabetes. Combining exenatide with dapagliflozin improved glycemic measures and cardiovascular risk factors more so than each drug alone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

· Nearly 50% Reduction in Diabetic Foot Ulcers With Stem Cells. Local injection of mesenchymal stem cells derived from autologous bone marrow shows promise in healing recalcitrant neuropathic diabetic foot ulcers, a novel study from Egypt shows.

· A novel implanted continuous glucose sensor is safe and accurately reflected blood glucose levels for an average of about 6 months, study results show.

· Continuous glucose monitoring (CGM) increased the time spent in glucose target range and cut the risk of severe hypoglycemia in patients with type 1 diabetes who have impaired hypoglycemia awareness, new research indicates.

· Use of the Freestyle Libre Flash Glucose Monitoring System significantly reduces hypoglycemia without raising HbA1c levels in insulin-treated diabetes patients, compared with self-monitoring of blood glucose using finger sticks, new research shows.

· Newly published pivotal trial data for the closed-loop insulin-delivery system, also known as the “artificial pancreas,” in patients with type 1 diabetes show use of the system resulted in reductions in both hypoglycemia and hyperglycemia with less glycemic variability compared with baseline data.

· Risk of perinatal death was increased by 30%, compared with the risk in nondiabetic mothers, in mothers with gestational diabetes who gave birth after 37 weeks, a large new cohort study from France shows.

· Ten Biomarkers (N-terminal pro-B-type natriuretic peptide (NT-proBNP, Trefoil factor 3, Growth/differentiation factor 15, Apolipoprotein B, Angiopoietin-2, Osteoprotegerin, α-2-macroglobulin, Hepatocyte growth factor receptor, Glutathione S transferase α and Chromogranin A) Predict CV Outcomes in Diabetes Patients.

· People with insulin-treated diabetes can be safe air pilots, new data from the United Kingdom indicate.

· The glucagonlike-peptide 2 (GLP-1) agonist Liraglutide delays progression of renal events — in particular, new-onset persistent macroalbuminuria — in patients with type 2 diabetes, according to the latest data from the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results—A Long Term Evaluation (LEADER) trial.